InMed Pharmaceuticals, Inc. (INM)
1.59
0.00 (0.00%)
USD |
NASDAQ |
Oct 27, 16:00
1.58
-0.01
(-0.63%)
After-Hours: 20:00
InMed Pharmaceuticals Free Cash Flow : -8.628M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -8.628M |
| March 31, 2026 | -8.040M |
| December 31, 2025 | -7.843M |
| September 30, 2025 | -7.940M |
| June 30, 2025 | -8.159M |
| March 31, 2025 | -6.800M |
| December 31, 2024 | -7.202M |
| September 30, 2024 | -6.580M |
| June 30, 2024 | -6.928M |
| March 31, 2024 | -6.861M |
| December 31, 2023 | -6.552M |
| September 30, 2023 | -7.343M |
| June 30, 2023 | -7.424M |
| March 31, 2023 | -10.52M |
| December 31, 2022 | -14.14M |
| September 30, 2022 | -15.09M |
| June 30, 2022 | -15.49M |
| March 31, 2022 | -13.70M |
| December 31, 2021 | -14.02M |
| September 30, 2021 | -11.51M |
| June 30, 2021 | -10.23M |
| March 31, 2021 | -9.275M |
| December 31, 2020 | -5.157M |
| September 30, 2020 | -6.162M |
| June 30, 2020 | -7.188M |
| Date | Value |
|---|---|
| March 31, 2020 | -7.727M |
| December 31, 2019 | -8.328M |
| September 30, 2019 | -7.658M |
| June 30, 2019 | -6.580M |
| March 31, 2019 | -5.804M |
| December 31, 2018 | -4.486M |
| September 30, 2018 | -3.901M |
| June 30, 2018 | -3.662M |
| March 31, 2018 | -3.399M |
| December 31, 2017 | -3.390M |
| September 30, 2017 | -3.221M |
| June 30, 2017 | -2.307M |
| March 31, 2017 | -1.651M |
| December 31, 2016 | -0.9576M |
| September 30, 2016 | -0.4231M |
| June 30, 2016 | -0.3884M |
| March 31, 2016 | -1.058M |
| December 31, 2015 | -1.670M |
| September 30, 2015 | -1.648M |
| June 30, 2015 | -1.623M |
| March 31, 2015 | -1.491M |
| December 31, 2014 | -0.8176M |
| September 30, 2014 | -0.7319M |
| June 30, 2014 | -0.6294M |
| March 31, 2014 | 0.0001M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| NervGen Pharma Corp. | -18.43M |
| Milestone Pharmaceuticals, Inc. | -61.10M |
| Appili Therapeutics, Inc. | -1.022M |
| Clearmind Medicine, Inc. | -6.997M |
| Lexaria Bioscience Corp. | -7.527M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -2.909M |
| Cash from Financing (Quarterly) | -0.0008M |
| Free Cash Flow Per Share (Quarterly) | -0.6653 |
| Free Cash Flow to Equity (Quarterly) | -2.489M |
| Free Cash Flow to Firm (Quarterly) | -2.899M |
| Free Cash Flow Yield | -132.9% |